Literature DB >> 31425693

Prevalence, risk factors, and surveillance patterns for gastric intestinal metaplasia among patients undergoing upper endoscopy with biopsy.

Robert J Huang1, Alexander R Ende2, Anand Singla2, Jennifer T Higa3, Alyssa Y Choi2, Ann B Lee2, Stella G Whang2, Kayla Gravelle2, Samantha D'Andrea2, Sung Jo Bang2, Rodney A Schmidt4, Matthew M Yeh4, Joo Ha Hwang1.   

Abstract

BACKGROUND AND AIMS: Gastric intestinal metaplasia (GIM) is an important precursor lesion to gastric cancer (GC), the second leading cause of cancer death worldwide. There exist few data regarding the prevalence of, risk factors for, and clinical practice patterns regarding GIM in the United States. Furthermore, there are currently no U.S. guidelines regarding screening/surveillance for GIM.
METHODS: All consecutive upper endoscopic procedures from 2 academic medical centers in Seattle between 1999 and 2014 were reviewed. Demographic, clinical, and endoscopic covariates were recorded at time of endoscopy. Procedures with gastric biopsy were matched to final the histologic diagnoses, including the presence of Helicobacter pylori. Cases of GIM and dysplasia were recorded and compared with non-GIM controls using univariate and multivariable regression. Surveillance patterns for cases of GIM were recorded.
RESULTS: Data from 36,799 upper endoscopies, 17,710 gastric biopsies, 2073 cases of GIM, 43 cases of dysplasia, and 78 cases of GC were captured. The point prevalence of GIM was 11.7% in patients who underwent gastric biopsy. Non-white race (P < .001), increasing age (P < .001), and presence of H pylori (P < .001) were associated with GIM. If GIM was present, increasing age (P < .001) and male gender (P < .001) were associated with progression, and the presence of H pylori (P < .001) was inversely associated with progression to dysplasia/GC. Few cases of GIM/dysplasia/GC were identified during procedures for GIM screening/surveillance. Only 16% of patients with a diagnosis of GIM received a recommendation for surveillance.
CONCLUSIONS: There is a high prevalence of GIM among non-white and Hispanic Americans. Risk factors for development of GIM may be distinct from the risk factors for progression to GC.
Copyright © 2020 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31425693     DOI: 10.1016/j.gie.2019.07.038

Source DB:  PubMed          Journal:  Gastrointest Endosc        ISSN: 0016-5107            Impact factor:   9.427


  13 in total

1.  A Comparison of Logistic Regression Against Machine Learning Algorithms for Gastric Cancer Risk Prediction Within Real-World Clinical Data Streams.

Authors:  Robert J Huang; Nicole Sung-Eun Kwon; Yutaka Tomizawa; Alyssa Y Choi; Tina Hernandez-Boussard; Joo Ha Hwang
Journal:  JCO Clin Cancer Inform       Date:  2022-06

2.  Management of gastric intestinal metaplasia in patients undergoing routine endoscopy before bariatric surgery.

Authors:  Yilon Lima Cheng; Enrique F Elli
Journal:  Updates Surg       Date:  2021-09-29

3.  Prevalence of Extensive and Limited Gastric Intestinal Metaplasia and Progression to Dysplasia and Gastric Cancer.

Authors:  Monika Laszkowska; Han Truong; Adam S Faye; Judith Kim; Sarah Xinhui Tan; Francesca Lim; Julian A Abrams; Chin Hur
Journal:  Dig Dis Sci       Date:  2021-10-17       Impact factor: 3.487

4.  A Summary of the 2020 Gastric Cancer Summit at Stanford University.

Authors:  Robert J Huang; Howard Koh; Joo Ha Hwang
Journal:  Gastroenterology       Date:  2020-07-21       Impact factor: 22.682

Review 5.  Improving the Early Diagnosis of Gastric Cancer.

Authors:  Robert J Huang; Joo Ha Hwang
Journal:  Gastrointest Endosc Clin N Am       Date:  2021-07

6.  Significance of pepsinogen in screening for gastric intestinal metaplasia in Guangdong, China.

Authors:  Xujuan Liu; Min Zhang; Riyu Luo; Keran Mo; Xingxiang He
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

7.  Prevalence of Gastric Intestinal Metaplasia in a Multiethnic US Veterans Population.

Authors:  Theresa H Nguyen; Mimi C Tan; Yan Liu; Massimo Rugge; Aaron P Thrift; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2020-03-14       Impact factor: 11.382

8.  The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions.

Authors:  M Blanca Piazuelo; Luis E Bravo; Robertino M Mera; M Constanza Camargo; Juan C Bravo; Alberto G Delgado; M Kay Washington; Alicia Rosero; Luz S Garcia; Jose L Realpe; Sandra P Cifuentes; Douglas R Morgan; Richard M Peek; Pelayo Correa; Keith T Wilson
Journal:  Gastroenterology       Date:  2020-11-18       Impact factor: 22.682

9.  Cytokine TGF-β1, TNF-α, IFN-γ and IL-6 Gene Polymorphisms and Localization of Premalignant Gastric Lesions in Immunohistochemically H. pylori-negative Patients.

Authors:  Anca Negovan; Mihaela Iancu; Florin Tripon; Andrei Crauciuc; Simona Mocan; Claudia Bănescu
Journal:  Int J Med Sci       Date:  2021-05-21       Impact factor: 3.738

10.  Dose-dependent association of proton pump inhibitors use with gastric intestinal metaplasia among Helicobacter pylori-positive patients.

Authors:  Yifat Snir; Haim Leibovitzh; Yaara Leibovici-Weissman; Alex Vilkin; Arnon D Cohen; Tzippy Shochat; Yaron Niv; Iris Dotan; Ilan Feldhamer; Doron Boltin; Zohar Levi
Journal:  United European Gastroenterol J       Date:  2021-03-18       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.